Chip Stocks Down on Momentum and Not CPI, Bokeh's Forrest Says
Original Report
Kim Forrest, Bokeh Capital Partners chief investment officer, says Tuesday's selloff is just a pause in momentum for skyrocketing chip stocks, not a shock from a hotter-than-estimated inflation...
Kim Forrest, Bokeh Capital Partners chief investment officer, says Tuesday's selloff is just a pause in momentum for skyrocketing chip stocks, not a shock from a hotter-than-estimated inflation report. She speaks with Ed Ludlow and Caroline Hyde on "Bloomberg Tech." (Source: Bloomberg)
Glass House Analysis
Inflation is the silent tax that erodes purchasing power, hitting hardest those who can least afford it. When grocery bills rise faster than wages, families face impossible choices between food, medicine, and rent. Unlike market volatility that mainly affects investors, inflation touches everyone who buys groceries, fills a gas tank, or pays rent.
The implications extend beyond the immediate news cycle. Every economic development creates ripples that affect employment, prices, and opportunities in ways that may not be immediately visible but are deeply felt. By tracking these connections, we can better understand how the economy truly works—not as an abstract machine, but as a human system shaped by and shaping the lives of millions.
Enjoyed this analysis?
Get the Glass House Briefing every morning—market news that actually makes sense, delivered free to your inbox.
No spam. Unsubscribe anytime.
More Stories
OpenAI trial updates: Altman says Musk's exit was a 'morale boost' for some employees
Elon Musk is accusing OpenAI CEO Sam Altman and President Greg Brockman of trying to 'steal a charity.'
Senate confirms Kevin Warsh as Fed governor, clears way for chair vote
The upper chamber voted to approve Warsh's nomination by a 51-45 vote, on a mostly party-line basis.
Anthropic announces new Claude-powered legal software as SaaS stocks continue to struggle
Hims & Hers plummets 13% after first-quarter loss, weak earnings guidance
Hims & Hers reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform.